R&D News | pharmaphorum

News

MindMed says LSD-based therapy effective in anxiety

Psychedelic medicines specialist MindMed has said that its LSD-based treatment MM-120 has shown efficacy in a proof-of-concept study involving patients with generalised an

News

Pharnext hit again as rare disease drug flunks phase 3 test

French biotech Pharnext has seen the value of its shares collapse after it revealed that its lead drug, a treatment for Charcot-Marie-Tooth (CMT) disease, failed to make t

News

Daiichi Sankyo taps Depixus to speed RNA drug discovery

Daiichi Sankyo has made the development of RNA-based therapeutics and vaccines one of the pillars of its R&D operations and has turned to start-up Depixus to accelerat

News

Genentech confirms Magargee as permanent CEO

Roche’s Genentech unit has looked internally for its new chief executive, appointing Ashley Magargee to the role following the departure of Alexander Hardy last month.

News

Digitised pathology resource will speed HIV cancer R&D

A collection of clinical specimens that has been gathered from people living with HIV for almost 30 years has been given a digital makeover with the help of computational

News

AZ agrees $1.1bn deal to buy RSV jab developer Icosavax

Not content with taking on the respiratory syncytial virus (RSV) prevention market with its antibody-based therapy Beyfortus, AstraZeneca has agreed to buy US biotech Icos

MindMed says LSD-based therapy effective in anxiety

Pharnext hit again as rare disease drug flunks phase 3 test

Daiichi Sankyo taps Depixus to speed RNA drug discovery

Genentech confirms Magargee as permanent CEO

Digitised pathology resource will speed HIV cancer R&D

AZ agrees $1.1bn deal to buy RSV jab developer Icosavax

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks